Abstract
Bruxism is defined as a parafunctional activity during sleep or while awake that includes locking and grinding of teeth and clenching. It generates excessive occlusal force that may lead to implant failure. Therefore, diagnosis of bruxism and providing specific protocols such as occlusal splint and/or injection of botulinum toxin before implant installation are important to prevent increases the risk of implant failure in bruxism patients.
Implant complications are divided into early and late failures. Early failures are related to osseointegration and late failures are related to occlusal overload5,6.
Bruxism is related to the late failures such as implant fracture, screw loosening, screw fracture, fracture of prosthesis (ceramic or porcelain), severe marginal bone loss and decementation4,7. The failure rate is increased by intensity and frequency of excessive occlusal forces on dental implants due to bruxism. The direction of parafunctional forces affects the survival rate of implants and implant-supported prosthesis7.
Diagnosis of bruxism is complicated. The assessments of bruxism can be divided into non-instrumental and instrumental3.
Non-instrumental assessments include clinical inspection and self-reporting such as by filling questionnaires.
Clinical features of bruxism include hypertrophy of the masticatory muscles with linea alba on the intraoral cheek and/or indentation on the lip or tongue. Severe masticatory muscle pain or temporomandibular joint pain, extreme mechanical tooth wear (attrition) and complications of prosthesis may also be indicative of bruxism. Mechanical tooth wear is differentially diagnosed from chemical tooth wear caused by gastro-esophageal reflux. Attrition due to past bruxism that is not currently active is ruled out carefully during the assessment of current bruxism3,4.
Self-reports may reveal muscle and joint pain resulting from psychological conditions such as stress and anxiety. However, self-report have limitations because they might not reflect actual hyperactivity of masticatory muscles3.
The most commonly used method to treat bruxism is occlusal splint. It has been used to prevent mechanical tooth wear and to attenuate pain in masticatory muscles. Occlusal splint is a non-invasive treatment1. Its use distributes the occlusal force, resulting in favorable prognosis for dental implants and prostheses8. Injection of botulinum toxin into the masticatory muscles may be another option to treat bruxism. The effect of botulinum toxin is that it decrease muscle strength and mastication and thus reduces excessive parafunctional force to the tooth and temporomandibular joint9.
The correlation between bruxism and implant failure is still controversial. However, many studies have reported the positive association bruxism with implant complications3-5,7,8. Therefore, based on these reports, a specific protocol needs to be implemented before implant installation to prevent increases the risk of implant failure in bruxism patients.
Sufficient history taking such as experience of repetitive prosthesis failures and of nocturnal bruxism and careful clinical inspection of the evidence of bruxism are necessary before implant surgery. If you find such evidence by using non-instrumental and/or instrumental assessment, sufficiently explain to the patients that bruxism increases the risk of implant failure and emphasize the recommendation of an additional treatment such as occlusal splint and/or injection of botulinum toxin.
References
1. Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K. 2008; Bruxism physiology and pathology: an overview for clinicians. J Oral Rehabil. 35:476–94.
https://doi.org/10.1111/j.1365-2842.2008.01881.x
. DOI: 10.1111/j.1365-2842.2008.01881.x. PMID: 18557915.
2. Lobbezoo F, van der Zaag J, van Selms MK, Hamburger HL, Naeije M. 2008; Principles for the management of bruxism. J Oral Rehabil. 35:509–23.
https://doi.org/10.1111/j.1365-2842.2008.01853.x
. DOI: 10.1111/j.1365-2842.2008.01853.x. PMID: 18557917.
3. Lobbezoo F, Ahlberg J, Raphael KG, Wetselaar P, Glaros AG, Kato T, et al. 2018; International consensus on the assessment of bruxism: report of a work in progress. J Oral Rehabil. 45:837–44.
https://doi.org/10.1111/joor.12663
. DOI: 10.1111/joor.12663. PMID: 29926505. PMCID: PMC6287494.
4. Yu HC, Kim YK. 2020; Fractures of implant fixtures: a retroscccpective clinical study. Maxillofac Plast Reconstr Surg. 42:13.
https://doi.org/10.1186/s40902-020-00258-3
. DOI: 10.1186/s40902-020-00258-3. PMID: 32351913. PMCID: PMC7183517.
5. Albrektsson T. Donos N; Working Group 1. 2012; Implant survival and complications. The third EAO consensus conference 2012. Clin Oral Implants Res. 23 Suppl 6:63–5.
https://doi.org/10.1111/j.1600-0501.2012.02557.x
. DOI: 10.1111/j.1600-0501.2012.02557.x. PMID: 23062128.
6. Manfredini D, Poggio CE, Lobbezoo F. 2014; Is bruxism a risk factor for dental implants? A systematic review of the literature. Clin Implant Dent Relat Res. 16:460–9.
https://doi.org/10.1111/cid.12015
. DOI: 10.1111/cid.12015. PMID: 23151302.
7. Chitumalla R, Halini Kumari KV, Mohapatra A, Parihar AS, Anand KS, Katragadda P. 2018; Assessment of survival rate of dental implants in patients with bruxism: a 5-year retrospective study. Contemp Clin Dent. 9(Suppl 2):S278–82.
https://doi.org/10.4103/ccd.ccd_258_18
. DOI: 10.4103/ccd.ccd_258_18. PMID: 30294158. PMCID: PMC6169261.
8. Tosun T, Karabuda C, Cuhadaroglu C. 2003; Evaluation of sleep bruxism by polysomnographic analysis in patients with dental implants. Int J Oral Maxillofac Implants. 18:286–92. PMID: 12705309.
9. Fernández-Núñez T, Amghar-Maach S, Gay-Escoda C. 2019; Efficacy of botulinum toxin in the treatment of bruxism: systematic review. Med Oral Patol Oral Cir Bucal. 24:e416–24.
https://doi.org/10.4317/medoral.22923
. DOI: 10.4317/medoral.22923. PMID: 31246937. PMCID: PMC6667018.